Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
ISO 15197‑15: Technical Requirements for Blood‑Glucose Monitoring Systems for Self‑Testing
Canadian Adoption (CAN/CSA‑ISO 15197:15) of International Accuracy and Performance Standards for Diabetes Management
Scope and Field of Application
ISO 15197‑15 (CAN/CSA‑ISO 15197:15) is the Canadian adoption of the international standard ISO 15197:2013, “In vitro diagnostic test systems — Requirements for blood‑glucose monitoring systems for self‑testing in managing diabetes mellitus.” It applies to blood‑glucose monitoring systems (BGMS) intended for use by laypersons at home, covering the entire system: meter, test strips, control solutions, and all accessories.
The standard defines essential performance requirements to ensure that self‑monitored glucose results are sufficiently accurate for clinical decision‑making. It also outlines evaluation procedures for manufacturers and conformity‑assessment bodies. Health Canada recognizes ISO 15197‑15 as the benchmark for pre‑market review of BGMS sold in Canada, aligning with the international consensus on quality and safety.
Tip: Although the document number includes “‑15”, the technical content is identical to ISO 15197:2013. The “15” denotes the year of Canadian adoption (2015), and the standard was reconfirmed in 2019.
Key Technical Requirements
System Accuracy Criteria
The core of ISO 15197‑15 is the accuracy requirement expressed as the agreement between BGMS results and a reference method (e.g., hexokinase or glucose oxidase on a clinical analyzer). The acceptance criteria differ by glucose concentration range:
| Glucose Concentration | Accuracy Criterion (95 % of results shall fall within) |
|---|---|
| < 5.6 mmol/L (100 mg/dL) | ±0.83 mmol/L (15 mg/dL) of the reference value |
| ≥ 5.6 mmol/L (100 mg/dL) | ±15 % of the reference value |
Additionally, in the lower concentration range (< 5.6 mmol/L), at least 99 % of results must fall within ±1.67 mmol/L (30 mg/dL) or ±30 % (whichever is greater). The standard mandates that accuracy be verified by at least 100 capillary blood samples from a diverse subject population, tested in triplicate with at least three different reagent lot numbers.
Interference and Robustness
ISO 15197‑15 requires manufacturers to evaluate the effect of endogenous and exogenous interfering substances. The user‑performed test must maintain accuracy in the presence of:
- Hematocrit – at least 30 % to 55 % range must be covered; systems must show bias ≤ 0.11 mmol/L per 10 % change in hematocrit.
- Reducing substances (e.g., ascorbic acid, uric acid, acetaminophen, dopamine) – each tested at clinically relevant concentrations.
- Variations in temperature, humidity, and altitude – performance must be documented across manufacturer‑claimed operating ranges.
Warning: Hematocrit interference remains a leading cause of bias in many BGMS. Systems that fail to compensate for hematocrit variation may produce falsely high or low readings in anemic or polycythemic patients, potentially leading to incorrect insulin dosing.
User Performance Evaluation
An essential requirement is demonstration that lay users can obtain accurate results under real‑life conditions. The standard calls for a clinical study involving at least 100 untrained subjects who read the instructions and perform a capillary blood test on themselves. The acceptance criterion is the same as for system accuracy (see table above). If the system includes alternate‑site testing (e.g., forearm), similar studies must be performed for each site.
Implementation and Verification
Manufacturer Considerations
To comply with ISO 15197‑15, manufacturers must design BGMS that minimize systematic biases and random errors. The development process typically includes:
- Reagent strip chemistry – must be stable over the claimed shelf life and open‑vial period.
- Meter algorithm – calibration curves must be robust to lot‑to‑lot variability and environmental stress.
- Meter design – user interface, display, and data handling must follow good usability engineering practices.
- Quality management – production and quality control must be in line with ISO 13485.
Conformity Assessment
In Canada, Health Canada recognizes ISO 15197‑15 as a special control for class III BGMS. Manufacturers submit a pre‑market application (Medical Device License) that includes the full evaluation dossier: accuracy studies, interference tests, user study, and stability data. A conformity‑assessment body (e.g., CSA Group) may audit the manufacturer’s quality system and review the technical documentation against the standard’s requirements.
Compliance and Regulatory Notes
Compliance benefit: Demonstrating full compliance with ISO 15197‑15 not only satisfies Canadian regulatory requirements but also facilitates market access in many other jurisdictions that accept the international standard (e.g., EU, Australia, Japan).
Non‑compliance risk: BGMS that fail to meet the accuracy criteria present a significant risk to patient safety. Health Canada has issued recalls and market withdrawals for systems that could not maintain the required ±15 % / ±0.83 mmol/L limits.
Manufacturers should also note that ISO 15197:2013 (and thus ISO 15197‑15) is under periodic review. A revision is expected in the coming years, potentially tightening the accuracy criteria (e.g., moving to ±10 % above 5.6 mmol/L). Staying informed of the standard’s evolution is essential for long‑term product compliance.
Frequently Asked Questions
Q: How does ISO 15197‑15 differ from the earlier ISO 15197:2003?
A: The 2003 version allowed ±20 % above 4.2 mmol/L. The 2013 revision (adopted as ISO 15197‑15) tightened the requirement to ±15 % above 5.6 mmol/L and added the 99 % lower limit for very low concentrations. The user‑performance study requirement was also made more rigorous.
A: The 2003 version allowed ±20 % above 4.2 mmol/L. The 2013 revision (adopted as ISO 15197‑15) tightened the requirement to ±15 % above 5.6 mmol/L and added the 99 % lower limit for very low concentrations. The user‑performance study requirement was also made more rigorous.
Q: Is ISO 15197‑15 mandatory for all blood glucose meters sold in Canada?
A: Yes. Health Canada requires Class III BGMS to meet the performance criteria of CAN/CSA‑ISO 15197:15. Manufacturers must provide evidence of compliance as part of the Medical Device Licensing process.
A: Yes. Health Canada requires Class III BGMS to meet the performance criteria of CAN/CSA‑ISO 15197:15. Manufacturers must provide evidence of compliance as part of the Medical Device Licensing process.
Q: Can a BGMS be compliant if it fails one interference test?
A: The standard requires that all claimed interferents be tested and that any bias exceeding the acceptance threshold be clearly stated in the labelling. A system may still be considered compliant if the observed interference is disclosed and does not affect the overall accuracy in normal use. However, substantial bias that renders results clinically misleading would lead to non‑compliance.
A: The standard requires that all claimed interferents be tested and that any bias exceeding the acceptance threshold be clearly stated in the labelling. A system may still be considered compliant if the observed interference is disclosed and does not affect the overall accuracy in normal use. However, substantial bias that renders results clinically misleading would lead to non‑compliance.
Q: Are continuous glucose monitors (CGM) covered by ISO 15197‑15?
A: No. ISO 15197‑15 specifically addresses self‑monitoring blood glucose (SMBG) systems using capillary blood. CGM devices fall under other standards, such as ISO 15197‑3? (currently under development) and the forthcoming ISO 15197‑2. Separate performance requirements and evaluation methods apply.
A: No. ISO 15197‑15 specifically addresses self‑monitoring blood glucose (SMBG) systems using capillary blood. CGM devices fall under other standards, such as ISO 15197‑3? (currently under development) and the forthcoming ISO 15197‑2. Separate performance requirements and evaluation methods apply.
— Updated 2026 —